Wall Street brokerages predict that Sensus Healthcare Inc (NASDAQ:SRTS) will report earnings per share (EPS) of ($0.20) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Sensus Healthcare’s earnings, with the lowest EPS estimate coming in at ($0.21) and the highest estimate coming in at ($0.18). Sensus Healthcare posted earnings of $0.01 per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 2,100%. The company is scheduled to report its next earnings report on Thursday, August 13th.
On average, analysts expect that Sensus Healthcare will report full year earnings of ($0.59) per share for the current fiscal year, with EPS estimates ranging from ($0.81) to ($0.42). For the next financial year, analysts anticipate that the business will post earnings of ($0.12) per share, with EPS estimates ranging from ($0.46) to $0.10. Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow Sensus Healthcare.
Sensus Healthcare (NASDAQ:SRTS) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.04) by ($0.18). The firm had revenue of $1.68 million during the quarter, compared to analysts’ expectations of $6.20 million. Sensus Healthcare had a negative return on equity of 11.86% and a negative net margin of 13.47%.
Several large investors have recently modified their holdings of the stock. Garrison Bradford & Associates Inc. boosted its position in shares of Sensus Healthcare by 5.1% during the fourth quarter. Garrison Bradford & Associates Inc. now owns 61,400 shares of the company’s stock worth $217,000 after acquiring an additional 3,000 shares during the last quarter. Rench Wealth Management Inc. bought a new position in Sensus Healthcare during the first quarter valued at $113,000. Mairs & Power INC bought a new position in Sensus Healthcare during the fourth quarter valued at $48,000. Morgan Stanley lifted its position in Sensus Healthcare by 12,595.0% during the first quarter. Morgan Stanley now owns 12,695 shares of the company’s stock valued at $32,000 after purchasing an additional 12,595 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in Sensus Healthcare during the fourth quarter valued at $35,000. Hedge funds and other institutional investors own 9.20% of the company’s stock.
Shares of NASDAQ SRTS traded up $0.28 during midday trading on Tuesday, reaching $3.09. The stock had a trading volume of 63,611 shares, compared to its average volume of 33,560. The stock has a 50-day moving average of $2.36 and a 200-day moving average of $3.32. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.54 and a current ratio of 5.24. The company has a market capitalization of $39.47 million, a price-to-earnings ratio of -14.79 and a beta of 0.21. Sensus Healthcare has a 12-month low of $1.76 and a 12-month high of $6.58.
Sensus Healthcare Company Profile
Sensus Healthcare, Inc manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
See Also: Net Income
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.